Cystatin C estimated glomerular filtration rate | lnAlbumin creatinine ratio (ACR) | |||
---|---|---|---|---|
total cohort (n = 647) | eGFR > 60 ml/min/1.73 m2 (n = 514) | total cohort (n = 647) | ACR < 3 mg/mmol (n = 522) | |
β-coefficient (95% CI) | β-coefficient (95% CI) | β-coefficient (95% CI) | β-coefficient (95% CI) | |
Model A | ||||
ln CRP (mg/L) | −0.23 (−0.30 to −0.15)*** | −0.10 (−0.17 to −0.34)** | 0.11 (0.03 to 0.19) ** | 0.07 (−0.04 to 0.06) |
ln PGF2α (nmol/mmol) | −0.01 (−0.07 to 0.08) | −0.01(−0.08 to −0.05) | 0.01 (−0.07 to 0.09) | 0.05 (0.002 to 0.10) * |
ln IL-6 (ng/L) | −0.28 (−0.35 to −0.20)*** | −0.10 (−0.17 to −0.04) ** | 0.13 (0.06 to 0.21) ** | 0.01 (−0.04 to 0.05) |
ln SAA (mg/L) | −0.15 (−0.22 to-0.07)*** | −0.05 (−0.12 to 0.02) | 0.14 (0.06 to 0.21) ** | 0.05 (0.002 to 0.10) * |
Model B (DAG adjusted) | ||||
ln CRP (mg/L) | −0.19 (−0.26 to −0.11)*** | −0.09 (−0.16 to −0.02) ** | 0.09 (0.01 to 0.16) * | −0.01 (−0.05 to 0.04) |
ln PGF2α (nmol/mmol) | −0.01 (−0.07 to 0.08) | −0.02 (−0.09 to 0.04) | 0.01 (−0.06 to 0.09) | 0.03 (−0.01 to 0.08) |
ln IL-6 (ng/L) | −0.23 (−0.30 to −0.15) *** | −0.09 (−0.16 to −0.02)* | 0.11 (0.03 to 0.19) ** | −0.01 (−0.05 to 0.04) |
ln SAA (mg/L) | −0.13 (−0.21 to −0.06)** | −0.05 (−0.12 to 0.02) | 0.12 (0.05 to 0.20) ** | 0.04 (−0.008 to 0.09) |
Model C | ||||
ln CRP (mg/L) | −0.19 (−0.26 to −0.11)*** | −0.09 (−0.16 to −0.02)** | 0.08 (0.01 to 0.16) * | −0.01 (−0.06 to 0.04) |
ln PGF2α (nmol/mmol) | −0.01 (−0.07 to 0.08) | −0.02 (−0.09 to 0.04) | −0.04 (−0.08 to 0.07) | 0.03 (−0.02 to 0.08) |
ln IL-6 (ng/L) | −0.23 (−0.30 to −0.15)*** | −0.09 (−0.16 to −0.02)** | 0.09 (0.01 to 0.16) * | −0.01 (−0.06 to 0.04) |
ln SAA (mg/L) | −0.13 (−0.21 to −0.06)*** | −0.05 (−0.12 to 0.02) | 0.11 (0.04 to 0.19) ** | 0.04 (−0.01 to 0.09) |